Team

Kristin Polsenski, M.B.A., is the Vice President of Portfolio, Program and Alliance Management of Recludix Pharma. Prior to joining Recludix, Ms. Polsenski was an independent consultant supporting multiple biotech companies in designing, developing and executing their program and alliance management activities, as well as clinical development programs. Previously, Ms. Polsenski was the Senior Director and Head of Program and Alliance Management at Zymeworks where she led the diligence for the 2022 ZIIHERA® (zanidatamab-hrii) licensing deal with Jazz Pharmaceuticals. Prior to Zymeworks, Ms. Polsenski oversaw the portfolio of clinical studies of ADCETRIS® (brentuximab vedotin) for Seagen (formally Seattle Genetics), playing an integral part in clinical program strategy, development and execution. She has held clinical and research roles at other top-tier drug development organizations, including Gilead Sciences, Jazz Pharmaceuticals, and Amgen. Ms. Polsenski obtained her B.S. in biology from University of Maryland, College Park and her M.B.A. from San Fransico State University.